Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity

Nature Biotechnology

Volumn 31, Issue 11, 2013, Pages 1047-1052

  Song, Ruijiang ^a   Oren, Deena A ^a   Franco, David ^a   Seaman, Michael S ^b   Ho, David D ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE GLYCOPROTEINS; HIV-1 INFECTIONS; HUMANIZED MONOCLONAL ANTIBODY; LIGHT CHAIN; N-LINKED GLYCANS; STERIC HINDRANCES; STRATEGIC PLACEMENT; VARIABLE REGIONS;

CHAINS; MONOCLONAL ANTIBODIES; POLYSACCHARIDES;

DISEASES;

GLYCAN DERIVATIVE; GLYCOPROTEIN GP 120; IBALIZUMAB;

AMINO TERMINAL SEQUENCE; ANTIBODY BLOOD LEVEL; ARTICLE; CARBOHYDRATE ANALYSIS; GENETIC ENGINEERING; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIGHT CHAIN; NONHUMAN; PRIORITY JOURNAL; STEREOSPECIFICITY; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; CROSS REACTIONS; DRUG RESISTANCE, VIRAL; HEK293 CELLS; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MODELS, MOLECULAR; POLYSACCHARIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84887474033     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2677     Document Type: Article

References (38)

1. Baeten, J.M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399-410 (2012).
2. Thigpen, M.C. et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367, 423-434 (2012).
3. Van Damme, L. et al. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367, 411-422 (2012).
4. Huber, M., Olson, W.C. & Trkola, A. Antibodies for HIV treatment and prevention: window of opportunity? Curr. Top. Microbiol. Immunol. 317, 39-66 (2008).
5. Baba, T.W. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6, 200-206 (2000).
6. Mascola, J.R. et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009-4018 (1999).
7. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
8. Walker, L.M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
9. Scheid, J.F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011).
10. Walker, L.M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
11. Moldt, B. et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. USA 109, 18921-18925 (2012).
12. Diskin, R. et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334, 1289-1293 (2011).
13. Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406-412 (2012).
14. Balazs, A.B. et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481, 81-84 (2011).
15. Jacobson, J.M. et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J. Infect. Dis. 198, 1345-1352 (2008).
16. Burkly, L.C. et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J. Immunol. 149, 1779-1787 (1992).
17. Jacobson, J.M. et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob. Agents Chemother. 53, 450-457 (2009).
18. Dimitrov, A. Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection. Curr. Opin. Investig. Drugs 8, 653-661 (2007).
19. Kuritzkes, D.R. et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. 189, 286-291 (2004).
20. Zhang, X.Q., Sorensen, M., Fung, M. & Schooley, R.T. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob. Agents Chemother. 50, 2231-2233 (2006).
21. Boon, L. et al. Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. Toxicology 172, 191-203 (2002).
22. Song, R. et al. Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J. Virol. 84, 6935-6942 (2010).
23. Freeman, M.M. et al. Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody. Structure 18, 1632-1641 (2010).
24. Toma, J. et al. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. J. Virol. 85, 3872-3880 (2011).
25. Pace, C.S. et al. Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J. Acquir. Immune Defic. Syndr. 62, 1-9 (2013).
26. Olden, K., Pratt, R.M. & Yamada, K.M. Role of carbohydrates in protein secretion and turnover: effects of tunicamycin on the major cell surface glycoprotein of chick embryo fibroblasts. Cell 13, 461-473 (1978).
27. Vallee, F., Karaveg, K., Herscovics, A., Moremen, K.W. & Howell, P.L. Structural basis for catalysis and inhibition of N-glycan processing class I alpha 1,2-mannosidases. J. Biol. Chem. 275, 41287-41298 (2000).
28. Reeves, P.J., Callewaert, N., Contreras, R. & Khorana, H.G. Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N- acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc. Natl. Acad. Sci. USA 99, 13419-13424 (2002).
29. Haynes, B.F. et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906-1908 (2005).
30. Mouquet, H. et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467, 591-595 (2010).
31. Pace, C.S. et al. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc. Natl. Acad. Sci. USA 110, 13540-13545 (2013).
32. Arnold, J.N., Wormald, M.R., Sim, R.B., Rudd, P.M. & Dwek, R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25, 21-50 (2007).
33. Anthony, R.M. & Ravetch, J.V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 30 (suppl. 1), S9-S14 (2010).
34. Nimmerjahn, F. & Ravetch, J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310, 1510-1512 (2005).
35. Pepinsky, R.B. et al. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci. 19, 954-966 (2010).
36. Wu, S.J. et al. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng. Des. Sel. 23, 643-651 (2010).
37. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
38. Seaman, M.S. et al. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single-or multi-clade HIV-1 envelope immunogens. Virology 367, 175-186 (2007).